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Abstract
Epidemiological research has shown there to be a strong relationship between preconceptional, prenatal, birth and early-
life factors and lifelong health. The Lifelines NEXT is a birth cohort designed to study the effects of intrinsic and extrinsic 
determinants on health and disease in a four-generation design. It is embedded within the Lifelines cohort study, a prospective 
three-generation population-based cohort study recording the health and health-related aspects of 167,729 individuals living 
in Northern Netherlands. In Lifelines NEXT we aim to include 1500 pregnant Lifelines participants and intensively follow 
them, their partners and their children until at least 1 year after birth. Longer-term follow-up of physical and psychological 
health will then be embedded following Lifelines procedures. During the Lifelines NEXT study period biomaterials—includ-
ing maternal and neonatal (cord) blood, placental tissue, feces, breast milk, nasal swabs and urine—will be collected from 
the mother and child at 10 time points. We will also collect data on medical, social, lifestyle and environmental factors via 
questionnaires at 14 different time points and continuous data via connected devices. The extensive collection of different 
(bio)materials from mother and child during pregnancy and afterwards will provide the means to relate environmental fac-
tors including maternal and neonatal microbiome composition) to (epi)genetics, health and developmental outcomes. The 
nesting of the study within Lifelines enables us to include preconceptional transgenerational data and can be used to identify 
other extended families within the cohort.
Keywords Biobank · Birth cohort · Prospective study · Microbiome · Transgenerational effects · Developmental Origins of 
Health and Disease (DOHaD)
Introduction
Exposures or events in the preconceptional, prenatal, birth 
and early life period may have lifelong effects on an indi-
vidual’s development and disease susceptibility. An impres-
sive body of evidence in the field of Developmental Origins 
of Health and Disease (DOHaD) has shown that maternal 
factors (e.g. physical and psychological health, lifestyle) and 
environmental factors can modulate the developmental pro-
gram [1–3]. This modulation could then permanently change 
the physiology, metabolism, epigenome and microbiome of 
the child, subsequently affecting healthy development or 
increasing susceptibility to (chronic) diseases [4–6]. Devel-
opmental programming via epigenetic changes may also 
have transgenerational effects without changing the genetic 
code in either the maternal or paternal line [7].
Several birth cohorts have been initiated with compre-
hensive data collection that include questionnaires as well 
as biomaterials to identify factors associated with child 
health and disease susceptibility [8]. However, although the 
importance of both immune status and the microbiome for 
the development of diseases has been established in mul-
tiple human cross-sectional studies and in animal models, 
only a few cohort studies include comprehensive immuno-
logical and microbiome data [9]. Moreover, very few birth 
cohorts have included three or more generations in their 
study design. * Willemijn D. B. Warmink-Perdijk  w.d.b.warmink@umcg.nl
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Another unique feature of the Lifelines NEXT data set 
is the presence of biomaterials from homebirths. In the 
Netherlands, 13% of children of mothers with low risk of 
complication are born at home [10]. This provides a unique 
opportunity to study the influence of homebirth versus birth 
in the hospital environment (with or without medical inter-
ventions) on the development of the newborn child. Previ-
ous work has found associations of birth interventions with 
increased risks of several immune-related diseases [11], 
but the mechanism(s) underlying this observation remain 
unclear. Data collected in Lifelines NEXT could assist in 
uncovering these mechanisms.
Finally, compared to other cohorts, Lifelines NEXT will 
collect large volumes of breastmilk over a long period of 
time [8]. This provides the means to study the mechanisms 
behind the immune-competent proteins in breastmilk, the 
large amounts of cholesterol it contains and the different 
molecular structures of its lipid content compared to infant 
formulas. Cellular trafficking from mother to child (“chi-
merism”) and (favorable) antigen exposition in an immune-
modulated neonatal environment have been suggested to be 
part of mechanisms that have a long-lasting effect on neo-
natal health and can be studied in Lifelines NEXT [12–15].
Lifelines NEXT is an observational prospective birth 
cohort with a transgenerational design of up to four gen-
erations. Lifelines NEXT is embedded within the previ-
ously described Lifelines cohort study [16, 17]. In short, 
Lifelines is a prospective population-based cohort study 
comprising approximately 10% of the population of the 
Northern Netherlands (the provinces of Groningen, Drenthe 
and Friesland). Lifelines includes 167,729 participants and 
was designed as a three-generation cohort [16, 17]. Within 
Lifelines, 112,596 participants (67%) have a known fam-
ily member within the cohort, with 84,888 (51%) part of 
two generations and 20,362 participants (12%) part of three 
generations of Lifelines participants [16]. Moreover, once 
genetic information becomes available, we anticipate that 
more extended families will be identified within the cohort 
given the expected cryptic genetic-relatedness of the more 
homogenous northern part of the Netherlands [18]. Initially, 
only children 8 years and older participated in Lifelines, and 
no data and materials were collected from Lifelines partici-
pants who became pregnant. With the initiation of Lifelines 
NEXT, we are filling this gap and adding a fourth generation 
to Lifelines.
The primary study objective of Lifelines NEXT is to 
investigate the effects of early life or pre-conceptional 
transgenerational events on health in early childhood. Its sec-
ondary aim is to correlate genomic, epigenetic, serological, 
metabolomic, microbiome, medical, social and environmen-
tal factors to early life health. Lifelines NEXT will provide 
unique opportunities to separate non-genetic from genetic 
familial transmission and to assess (epi)genetic influences 
and imprinting. Moreover, Lifelines NEXT can associate 
exposures in the preconception, prenatal, birth and early life 
period with healthy development and (chronic) disease sus-
ceptibility. The main risk factors of interest include microbi-
ome, (epi)genetic, environmental and lifestyle factors.
This paper describes the infrastructure of the detailed and 
unique (bio)data collection of Lifelines NEXT, which starts 
in early pregnancy (as early as 12 weeks gestational age) and 
follows the offspring extensively up until at least 12 months 
of age. The infrastructure of Lifelines will be used to extend 
children’s follow up and offers participants the opportunity 
to enter the regular Lifelines cohort including its standard-




Lifelines NEXT aims to include 1500 pregnant women. 
Upon inclusion, their partners are also invited to partici-
pate. Children are included in the birth cohort on the day 
they are born.
From 2016 to 2021, Lifelines NEXT will recruit pregnant 
women in the Northern part of the Netherlands, preferably 
from 12 weeks gestational age onwards. Eligible women 
are recruited via midwives or gynecologists, the Lifelines 
website, Lifelines NEXT social media (announcements on 
Facebook and Instagram), Lifelines newsletters, pregnancy-
related events and informational meetings. A leaflet con-
taining details about Lifelines NEXT is provided. Pregnant 
women who consent to participate in the study are contacted 
via the Lifelines service desk. A research assistant at the ser-
vice desk then provides more detailed information about the 
data collection of Lifelines NEXT (Fig. 1) and explains the 
informed consent procedure. A research nurse is allocated 
as the primary contact person for each Lifelines NEXT par-
ticipant and obtains the informed consent at the first home 
visit. Both parents need to consent that their child will be 
included in Lifelines NEXT.
Procedures for gathering and storage of (bio)
materials and data
Questionnaire data and extensive biomaterial data will be 
collected for the mother, father, child and the family home 
environment (Fig. 1). Data collection starts, preferably, at 
12 weeks of gestation. Research nurses will visit participants 
four times to perform tests and collect (bio)materials. To 
minimize the burden on the participants, sample collection 
is performed at the participant’s home by the research nurse, 
by the mother herself or by her maternity care provider. 
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This participant-based sampling program was designed 
using insights and experience gathered in similar success-
ful program like Lifelines DEEP [19]. To assist participants 
in this process, Lifelines NEXT provides standardized pro-
tocols for the collection and storage of (bio)samples. An 
overview of all (bio)materials collected during the study is 
shown in Table 1. Furthermore, questionnaires will be sent 
digitally by email at standardized time points. Table 2 pro-
vides a detailed overview of the measures that longitudinally 
assesses maternal, neonatal or paternal characteristics in the 
questionnaires.
Feces and breastmilk are sampled and aliquoted by the 
participant and stored, along with urine samples, in a freezer 
in the participant’s home (− 20 °C) until they are collected 
by the research nurse. The nurse ships the frozen samples 
to the Lifelines laboratory and biobank, where they are 
processed and then stored at − 80 °C. Venous blood and 
umbilical cord blood is drawn by allocated professionals, 
and samples are immediately stored in the refrigerator either 
at home or at the hospital (EDTA), kept for 30 min at room 
temperature and then refrigerated (serum), or kept at room 
temperature (PAXgene collection tubes). Blood samples are 
processed and divided into aliquots in the laboratory. Other 
biomaterials surrounding birth are collected and temporarily 
stored in a refrigerator (placenta biopsies) or freezer (vaginal 
swabs) located in either the participant’s homes (for home-
births) or at the hospital where the birth took place. These 
biomaterials are then transferred to the Lifelines laboratory 
and biobank within 10 h of birth. All materials are stored in 
barcoded aliquots at − 80 °C for future research, except for 
the blood spot collected at 4 months, which is kept at room 
temperature. All data are stored in a secured data storage 
environment.
Measurements of the mother
During pregnancy and the first year after childbirth, partici-
pating women are asked to complete eleven different ques-
tionnaires on their physical health, psychological health, 
reproductive health, lifestyle-related behavior and nutritional 
intake, and social and working conditions (Table 2). During 
the first home visit, a venous blood sample is drawn by the 
research nurse. Additionally, during the prenatal period and 
the first year post-partum, maternal biomaterials are sampled 
and stored by the participants themselves and collected at 
home visits by the research nurse (Fig. 1).
During childbirth, the maternity care provider will collect 
a vaginal swab, a fecal sample and blood from the mother. 
Fig. 1  Timeline of the Lifelines NEXT study indicating the data collection per time point. aOnly for non-Lifelines fathers. Measurements start at 
the moment of inclusion. bGestational age (weeks)/child’s age (months)
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Immediately after birth, umbilical cord blood and placental 
tissue are collected according to standardized protocols. The 
placenta is also weighed and photographed. Maternity care 
providers also provide a detailed birth report.
Measurements of the child
Children are included in the birth cohort on the day they are 
born. During the first year of follow-up, the parents com-
plete eight different questionnaires on their child’s health, 
development and behavior (Table 2). Seven fecal samples 
are collected over an interval that starts directly after birth 
and continues up until the child is 1 year of age. During a 
home visit at age 4 months, the research nurse will sample 
capillary blood by a puncture of the child’s heel. At age 
12 months, venous blood will be sampled at the pediatrics 
outpatient clinic at the University Medical Center Groningen 
(UMCG). Additionally, at the 4- and 12-month home visits, 
a mouth and a nose sample will be collected for microbiome, 
DNA and RNA profiling (Table 1). The research nurse will 
also assess the presence of eczema using the cumulative 
objective scoring index for atopic dermatitis (SCORAD) 
[20] (Table 2). During a separate home visit at 4 months of 
age, lung function tests will be performed with the Single 
Occlusion Technique (WHISTLER) by a dedicated research 
nurse [21, 22].
Measurements of the father
If the father consents to participate in Lifelines NEXT and 
is also a Lifelines participant, no additional (biomaterial) 
data needs to be collected. However, if the father is not a 
participant in Lifelines, he will be embedded in the routine 
data collection of Lifelines [16]. During a home visit, the 
research nurse will draw blood and perform anthropomet-
ric examinations that conform with the Lifelines protocol 
(Fig. 1, Table 1) [16]. Additionally, throughout the prena-
tal period, these fathers will complete three different Life-
lines baseline questionnaires with an interval of 10 weeks 
(Table 2) [16].
Measurements on the family home environment
Environmental data will be collected by measuring air qual-
ity in participant’s homes. Airborne dust will be collected 
with an electrostatic dust fall collector (EDC) [23] placed 
during a home visit at 28 gestational weeks and at 4-months 
postpartum (Table 1). The social conditions at home will 
also be assessed. Additional data will be collected using 
self-reported questionnaires that include items about the 
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pets (Table 2). Finally, regional data on air pollution will be 
collected by extracting geocoded data on postal code level.
The Newborn initiative
Lifelines NEXT participants also have the opportunity 
to participate in the Newborn initiative, a public–private 
project that expands the range of phenotypes measured 
through agreements with companies developing new tech-
nologies while looking at local public health issues. In liv-
ing lab Newborn, prototypes of innovative products that 
contribute to health can be tested in real-time home situa-
tions. Upon additional consent, these data can be used for 
product development. The Lifelines NEXT data collection 
will be enriched with data from continuous measurement 
devices with built-in apps, e.g. the heartbeat of the mother 
 (healthband®), air quality  (airvibe®) and behavior of the 
child (uGrow Baby  Monitor®).
Study organization
Lifelines NEXT is an initiative of the Departments of Genet-
ics, Obstetrics, Laboratory medicine and Pediatrics of the 
UMCG. The study is embedded in the organizational struc-
ture of the Lifelines cohort study and will use its service 
center, its laboratory for processing of biomaterials and its 
infrastructure for digital data collection and storage. All col-
lected biomaterials will be stored in labeled tubes in the 
Lifelines Lifestore, which currently holds more than 5 mil-
lion biomaterials of Lifelines participants [16].
The project is governed by a steering committee in which 
the UMCG Departments of Genetics, Pediatrics, Laboratory 
medicine, Obstetrics, Community and Occupational Health 
and Midwifery are represented, as well as the Lifelines 
organization. The chairman of the steering committee leads 
the project leaders, maintains contact with external sponsors 
and is accountable to the supervisory board. Moreover, a 
supervisory board is in charge consisting of the representa-
tives from the three UMCG Departments of Genetics, Labo-
ratory Medicine and Obstetrics and the board of the UMCG 
Hereditary Metabolic Diseases Fund. Project leaders from 
the UMCG and Lifelines work closely to manage the study.
Daily management of Lifelines NEXT is carried out by 
several members of the Lifelines NEXT research team. A 
Lifelines research assistant is the primary contact person 
for all the maternity healthcare providers involved who have 
questions related to (the data collection of) Lifelines NEXT. 
The research assistant also extensively monitors the Lifelines 
NEXT study process of each participant and schedules home 
visits according to the protocol. Outside normal working 
hours, a member of the birth team, which consists of medical 
and midwifery students, is available to support data collec-
tion at birth. All birth team members have been trained to 
collect biomaterials according to protocol, and they arrange 
the transportation of these biomaterials to the biobank 
within 3 h. A research nurse is allocated to be the primary 
contact person for each Lifelines NEXT participant and will 
perform all the home visits during the study. The research 
nurse distributes biomaterial collection sets, provides collec-
tion instructions and installs devices for environmental data 
collection. By staying in close contact with the participants, 
the research nurse acts as a confidant and is instrumental in 
ensuring that questionnaires are completed and biomaterials 
collected. Moreover, the research nurse gathers the biomate-
rials that were collected at home and arranges their transport 
to the Lifelines laboratory and biobank for processing and 
storage. All Lifelines NEXT data are stored in a secured data 
storage environment that utilizes MOLGENIS, a modular 
suite of web databases for integrating genotype, phenotype 
and other analyses. Each MOLGENIS database has web user 
interfaces as well as scriptable interfaces to plug-in R, Java 
and web services [46]. The handling of data complies with 
the General Data Protection Regulation (GDPR) [47].
Statistical power considerations and study size
Based on the Lifelines add-on study Lifelines DEEP 
(n = 1500), in which integrative analyses have been con-
ducted, a sample size of 1500 subjects will be sufficient to 
generate novel insights into the preconception, prenatal, 
birth and early life period [19]. In Lifelines DEEP we had 
enough power, for instance, to show statistically significant 
associations between specific microbial compositions and 
blood lipids [48] and to study various factors influencing 
microbiome composition and function [49]. These analyses 
were performed systematically on multiple factors and mul-
tiple levels, including microbial diversity, inter-individual 
distance in composition, individual species and pathway 
level.
Given a birth rate of 1.6 in the Netherlands [50] and 
the participation of approximately 40,000 women aged 
25–40 years in Lifelines, we expect about 2000 pregnan-
cies per year. Based on previous Lifelines add-on studies, 
we expect a response rate around 60% [19].
Harmonization and external database linkages
Harmonization and linkage with baseline and future lon-
gitudinally collected Lifelines data, including genome-
wide genetic data, will be established for all participants 
in Lifelines NEXT (i.e. the mother, father and child). 
This will result in data from up to four generations of the 
women in Lifelines NEXT. Data of the mothers participat-
ing in Lifelines NEXT will be linked with the Dutch Peri-
natal Data Register, Perined. This perinatal registration 
data includes three separate databases: one for primary 
Lifelines NEXT: a prospective birth cohort adding the next generation to the three-generation…
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midwife-led care, one for secondary obstetric care and one 
for neonatal care [11]. These three databases are combined 
into one national perinatal database via a validated link-
age method by the Perinatal Registry Office [51]. The data 
of the Lifelines NEXT children will be linked with the 
electronic files of the regional youth and family centers. 
These centers are entrusted with the national preventive 
follow-up program of children that monitors the health and 
development of children from birth until 18 years. This 
system sees over 95% of all children born in the Neth-
erlands through a comprehensive series of appointments 
[52]. Moreover, Lifelines NEXT data could be merged and 
harmonized with data collected by other cohort studies 
like the Netherlands Kinship Panel Study (NKPS) [53], 
the birth cohort studying the prevention and incidence of 
asthma and mite allergy (PIAMA) [54], Trails NEXT [55] 
and NeoLifeS [56].
Strengths and limitations
Lifelines NEXT will be a rich resource for research. It 
is a unique birth cohort that can address critical ques-
tions regarding the influence of environmental exposures, 
social factors, stressors and early-life nutrition on early 
life development. While the Lifeline NEXT cohort con-
sists of relatively healthy people, it is suitable for research 
related to (chronic) disease susceptibility (rather than rare 
diseases). It also enables study of the association of vari-
ations in microbiome, metabolomics profiles and (epi)
genomics in mothers and children with short- and longer-
term health outcomes. The dynamic organization of the 
study allows us to add additional measurements and to ask 
new questions during the course of the study. For example, 
we have already added sampling of feces at all time points 
in glycerol tubes that allow for later culturing of live bac-
teria, additional sampling of neonatal feces in week 2 and 
continuous measurements from connected devices to the 
study. Further add-on initiatives from additional research-
ers are also welcomed.
The extended hygiene hypothesis and the EPIgenetic 
Impact of Childbirth (EPIIC) hypothesis both suggest that 
factors occurring during the intrapartum and early postna-
tal period may affect the neonatal immune response or lead 
to different microbial communities and fetal epigenomic 
remodeling anomalies [58, 59]. Lifelines NEXT will be 
able to study different microbial communities of children 
by metagenomic sequencing, obtaining a comprehensive 
view of the development of microbial ecosystems in the 
early life period, as well as its relation to immune, respira-
tory and metabolic development. It will also be possible to 
study the change of epigenetic profiles in more detail, for 
instance that of genes related to allergy in the first years 
of life [60].
Another strength of Lifelines NEXT is that it offers 
the possibility to study interactions of immunological, 
microbial and metabolic maturation processes with envi-
ronmental factors such as mode of delivery, maternal and 
early neonatal feeding patterns, type of nutrition (such as 
breastmilk or formula), indoor and outdoor environmental 
factors (e.g. exposure to cigarette smoke, air pollution and 
allergens), use of medication and infections [12, 13, 15, 
61–66].
Finally, little attention has been paid thus far to the viral 
composition of the microbiome: the virome. Because major-
ity of gut viruses are viruses of bacteria (bacteriophages), 
they are therefore expected to be a major factor in shaping 
the human microbiome, and could exert an effect on human 
physiology [67]. So far, little research has been done look-
ing at the role of bacteriophages in the development of gut 
ecosystem, and their relation to babies health. Through com-
prehensive analysis, this relatively new area of the role of the 
virome can be studied in depth.
However, this study had some limitations. At first there 
is only a limited amount of data available on fathers that 
were not in the Lifelines study upon the pregnancy of their 
partners. To meet the need for background information, 
several baseline questionnaires of the initial Lifelines 
cohort study are included and will be completed by those 
new participants. A challenge is to include a representative 
sample for the Dutch population. As we know, the Life-
lines cohort study had, adjusted for differences in demo-
graphic composition, a smaller proportion of low edu-
cated participants and smokers. However the population 
was concluded to be broadly representative for the adult 
population of the north of the Netherlands [57]. Aiming 
to maintain generalizability we used similar recruitment 
techniques within Lifelines NEXT.
Collaboration
We expect inclusion to be completed in 2021, therefore 
from 2023 onwards biomaterials and data collected in 
Lifelines NEXT will be available to other researchers. In 
the meanwhile the Lifelines NEXT consortium welcomes 
collaboration with other birth cohorts. For example, Life-
lines NEXT data could be harmonized and merged with 
other European and Canadian birth cohorts as proposed 
in the EUCAN-Connect project [68]. We also welcome 
add-on initiatives. The Lifelines NEXT cohort study has 
an open protocol. Interested researchers can submit an 
application for an additional study or additional (biomate-
rial) data collection to the steering committee of Lifelines 
NEXT for approval. Further information can be requested 
by e-mail: (lifelinesnext@umcg.nl). The Lifelines website 
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(www.Lifel ines.nl) provides information about the appli-
cation process and the data collection, and gives an over-
view of all available data within Lifelines and publications 
with Lifelines data.
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